Caveolin-1 As A Novel Therapeutic Target For Breast Cancer: A Review Article | ||||
| Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology | ||||
| Volume 15, Issue 2, December 2023, Page 691-712 PDF (557.48 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/eajbsc.2023.327048 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Mohamed Hosney | ||||
| Zoology Department, Faculty of Science, Cairo University, 12613, Giza, Egypt. | ||||
| Abstract | ||||
| Numerous different cell groups, such as endothelial cells, pericytes, macrophages, mesenchymal stem cells, smooth muscle cells, and stromal fibroblasts, can be found in the tumor microenvironment Caveolin-1, which is also referred to as caveolin, Cav-1, or VIP21 is a structural membrane protein that has been demonstrated to suppress breast tumor growth and metastasis. Numerous studies have determined Cav-1 as a potential therapeutic target for breast cancer due to its inhibitory effects on cancer-associated pathways. In preclinical studies, expressed Cav-1 has been demonstrated to prevent breast tumor cell invasion, and the lack of stromal Cav-1 is linked to early breast cancer development. According to certain research, Cav-1 may also inhibit the late phase of autophagy via HIF-1 in triple-negative breast cancer. Furthermore, Cav-1 has been demonstrated to prevent breast tumor stem cells' self-renewal ability and aerobic glycolysis activity. These data show that Cav-1 may play an important function in breast tumor inhibition, as a possible target for treatment of breast cancer. | ||||
| Keywords | ||||
| Caveolae; Breast cancer; Caveolin-scaffolding domain; Tumor microenvironment; Caveolin-1 | ||||
|
Statistics Article View: 182 PDF Download: 241 |
||||
